Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells

(2014) Stuart J. Gallagher et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151

(2014) Stuart J. Gallagher et al.   Pigment Cell & Melanoma Research

Manipulating the PD-1 pathway to improve immunity

(2013) Alice O Kamphorst et al.   CURRENT OPINION IN IMMUNOLOGY

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

(2013) Omid Hamid et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

NF-κB Plays a Key Role in Inducing CD274 Expression in Human Monocytes after Lipopolysaccharide Treatment

(2013) Gang Huang et al.   PLoS One

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

NF- B, the first quarter-century: remarkable progress and outstanding questions

(2012) M. S. Hayden et al.   GENES & DEVELOPMENT

Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors

(2012) Stephen T. Smale   IMMUNOLOGICAL REVIEWS

NF-κB and the link between inflammation and cancer

(2012) Joseph A. DiDonato et al.   IMMUNOLOGICAL REVIEWS

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

(2012) Kavitha Gowrishankar et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

(2012) Fritz Lai et al.   MELANOMA RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment

(2011) Ning Li et al.   CANCER CELL

Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas

(2011) Jie Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Amino terminal hydrophobic import signals target the p14ARF tumor suppressor to the mitochondria

(2011) Mal Irvine et al.   CELL CYCLE

Suppression of inflammation by a synthetic histone mimic

(2010) Edwige Nicodeme et al.   NATURE

Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer

(2009) Sergei I. Grivennikov et al.   CYTOKINE & GROWTH FACTOR REVIEWS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA